- Price
- $13.56
- Day
- 0.00%
- Mkt Cap
- $3.56B
- 52W Range
- $5.69 – $13.60
- Volume
- 1.19M
- Beta
- 1.54
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company's Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE: OGN) is a global h.
Read full article
Organon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago.
Read full article
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read full article
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read full article
VANCOUVER, BC / ACCESS Newswire / July 27, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties for the first half of 2026 and forecast for the remainder of the year. Highlights Approximately 44,000 metres of partner-funded drilling completed or underway on seven exploration stage projects where Orogen holds various royalty interests Over 7,000 metres of conversion drilling completed at Ermitano's Navidad/Winter deposit, where Orogen holds a cash-flowing 2% net smelter return ("NSR") royalty Received $1.72 million from the sale of projects and payments from exploration partners year to date Two new royalties created from project sales New pipeline of projects generated from partner-funded gold exploration in Nevada and Utah, and from Orogen's internally funded programs Additional six drill programs with 25,000 metres of drilling estimated in H2-2026 Paddy Nicol, CEO of Orogen, commented, "Orogen's strategy is built on a scalable business model of profitably generating highly prospective exploration stage mineral projects and advancing them through strategic partnerships, while retaining royalties.
Read full article
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups.
Read full article
Shareholders of Organon & Co. NYSE: OGN approved the company's proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to preliminary voting results announced during the meeting.
Read full article
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will.
Read full article
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Read full article